Cargando…

Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases

BACKGROUND: In 2005 the Italian Medicines Agency (AIFA) started a program on independent research on drugs, with the aim to promote clinical research in areas of limited commercial interest. For 3 years (2005–2007) an area of the program was reserved to studies in the field of rare diseases. There i...

Descripción completa

Detalles Bibliográficos
Autores principales: Traversa, Giuseppe, Masiero, Lucia, Sagliocca, Luciano, Trotta, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828875/
https://www.ncbi.nlm.nih.gov/pubmed/27068647
http://dx.doi.org/10.1186/s13023-016-0420-4
_version_ 1782426669643988992
author Traversa, Giuseppe
Masiero, Lucia
Sagliocca, Luciano
Trotta, Francesco
author_facet Traversa, Giuseppe
Masiero, Lucia
Sagliocca, Luciano
Trotta, Francesco
author_sort Traversa, Giuseppe
collection PubMed
description BACKGROUND: In 2005 the Italian Medicines Agency (AIFA) started a program on independent research on drugs, with the aim to promote clinical research in areas of limited commercial interest. For 3 years (2005–2007) an area of the program was reserved to studies in the field of rare diseases. There is a concern that public funding of research may be wasted. We investigated the outcome of the program. METHODS: We conducted a cohort study on the projects that were funded by the AIFA in the area of rare diseases. The outcomes were the proportion of published studies, time to publication, impact factor of the publishing journals and relevance for clinical practice. We retrieved published articles through a literature search in peer reviewed biomedical journals indexed by Pubmed. We used the Kaplan–Meier method to estimate the cumulative probability of publication by time from project starting to publication. RESULTS: During the period 2005–2007, 62 projects were funded in the area of rare diseases. Most of the studies (n 39; 63 %) had a randomized design and in 22 (35 %) the control group received an active treatment. For 39 studies (63 %) we retrieved a publication in a peer reviewed journal. The median time to publication was 74 months and, at the maximum period of follow up (109 months), the cumulative probability of publication reached 77 %. The median impact factor was 5.4 (range 1.4–52.4). Considering the clinical relevance, more than 30 % of the published articles presented conclusive findings; an additional 10 % of the studies reached potential breakthrough findings. CONCLUSIONS: Even though it takes time to set up and conduct a funding program for independent research on drugs, the results are highly rewarding. Independent funding is crucial in supporting studies aimed at answering questions that are relevant for clinical practice despite the lack of sufficient commercial interest. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0420-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4828875
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48288752016-04-13 Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases Traversa, Giuseppe Masiero, Lucia Sagliocca, Luciano Trotta, Francesco Orphanet J Rare Dis Research BACKGROUND: In 2005 the Italian Medicines Agency (AIFA) started a program on independent research on drugs, with the aim to promote clinical research in areas of limited commercial interest. For 3 years (2005–2007) an area of the program was reserved to studies in the field of rare diseases. There is a concern that public funding of research may be wasted. We investigated the outcome of the program. METHODS: We conducted a cohort study on the projects that were funded by the AIFA in the area of rare diseases. The outcomes were the proportion of published studies, time to publication, impact factor of the publishing journals and relevance for clinical practice. We retrieved published articles through a literature search in peer reviewed biomedical journals indexed by Pubmed. We used the Kaplan–Meier method to estimate the cumulative probability of publication by time from project starting to publication. RESULTS: During the period 2005–2007, 62 projects were funded in the area of rare diseases. Most of the studies (n 39; 63 %) had a randomized design and in 22 (35 %) the control group received an active treatment. For 39 studies (63 %) we retrieved a publication in a peer reviewed journal. The median time to publication was 74 months and, at the maximum period of follow up (109 months), the cumulative probability of publication reached 77 %. The median impact factor was 5.4 (range 1.4–52.4). Considering the clinical relevance, more than 30 % of the published articles presented conclusive findings; an additional 10 % of the studies reached potential breakthrough findings. CONCLUSIONS: Even though it takes time to set up and conduct a funding program for independent research on drugs, the results are highly rewarding. Independent funding is crucial in supporting studies aimed at answering questions that are relevant for clinical practice despite the lack of sufficient commercial interest. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0420-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-12 /pmc/articles/PMC4828875/ /pubmed/27068647 http://dx.doi.org/10.1186/s13023-016-0420-4 Text en © Traversa et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Traversa, Giuseppe
Masiero, Lucia
Sagliocca, Luciano
Trotta, Francesco
Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases
title Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases
title_full Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases
title_fullStr Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases
title_full_unstemmed Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases
title_short Italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases
title_sort italian program for independent research on drugs: 10 year follow-up of funded studies in the area of rare diseases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828875/
https://www.ncbi.nlm.nih.gov/pubmed/27068647
http://dx.doi.org/10.1186/s13023-016-0420-4
work_keys_str_mv AT traversagiuseppe italianprogramforindependentresearchondrugs10yearfollowupoffundedstudiesintheareaofrarediseases
AT masierolucia italianprogramforindependentresearchondrugs10yearfollowupoffundedstudiesintheareaofrarediseases
AT saglioccaluciano italianprogramforindependentresearchondrugs10yearfollowupoffundedstudiesintheareaofrarediseases
AT trottafrancesco italianprogramforindependentresearchondrugs10yearfollowupoffundedstudiesintheareaofrarediseases